Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 5:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 685 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: CROHN'S DISEASE Clear all
Terminated No phase listed Observational

Volatiles in Exhaled Breath and Blood in Crohn's Disease: Validation Cohort

NCT02641171
View directory record Official record
Conditions
Crohn's Disease
Interventions
Specimen sampling
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Oct 10, 2026, 5:39 PM EDT
Completed No phase listed Observational

Stress in Crohn's Disease

NCT04809194
View directory record Official record
Conditions
Crohn Disease
Interventions
Not listed
Lead sponsor
4YouandMe
Other
Eligibility
18 Years to 65 Years
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 5, 2023 · Synced Oct 10, 2026, 5:39 PM EDT
Recruiting Phase 4 Interventional

Mirikizumab in the Treatment of Chronic Inflammatory Conditions of the Pouch

NCT06864403
View directory record Official record
Conditions
Pouchitis, Pouches, Ileoanal, Pouch, Ileal
Interventions
Mirikizumab - Intravenous (IV), Mirikizumab - Subcutaneous (SC)
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Los Angeles, California • Rochester, Minnesota • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 10, 2026, 5:39 PM EDT
Not listed Not applicable Interventional

Efficacy of a Low Fiber Diet for Pediatric Colonoscopy Prep

NCT05918562
View directory record Official record
Conditions
Colitis, Gastrointestinal Diseases, Pediatric Disorder, Pediatric Crohns Disease, Procedural Sequelae
Interventions
Low fiber diet, Standard clear liquid diet
Dietary Supplement
Lead sponsor
Rhode Island Hospital
Other
Eligibility
10 Years to 17 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Oct 10, 2026, 5:39 PM EDT
Completed Not applicable Interventional

Use of Psychologist-administered Cognitive Behavioral Therapy (CBT) or Self-administered CBT for the Treatment of Anxiety and/or Depression in Inflammatory Bowel Disease (IBD)

NCT05377840
View directory record Official record
Conditions
Crohn Disease, Ulcerative Colitis (UC)
Interventions
Psychologist-administered Cognitive Behavioral Therapy, Self-Administered Cognitive Behavioral Therapy
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 10, 2026, 5:39 PM EDT
Completed Phase 1 Interventional

FMT for Postop Crohn's Disease

NCT05248191
View directory record Official record
Conditions
Crohn Disease
Interventions
Capsule fecal microbiota material (cap-FMT), Colonoscopic fecal microbiota material (colo-FMT)
Biological
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 10, 2026, 5:39 PM EDT
Completed Phase 4 Interventional

Flagyl Microbiome in Crohn's Disease

NCT04682522
View directory record Official record
Conditions
Crohn Disease
Interventions
Metronidazole Oral
Drug
Lead sponsor
University of Louisville
Other
Eligibility
20 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Oct 10, 2026, 5:39 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Non-myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (NST) for Patients With Refractory Crohn's Disease

NCT01288053
View directory record Official record
Conditions
Crohn's Disease
Interventions
Allogeneic Stem Cell Therapy
Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 45 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Oct 10, 2026, 5:39 PM EDT
Completed Phase 2 Interventional Results available

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

NCT01276509
View directory record Official record
Conditions
Crohn's Disease
Interventions
PF-00547659 SC injection
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 75 Years
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
69
States / cities
Jonesboro, Arkansas • Little Rock, Arkansas • La Jolla, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2021 · Synced Oct 10, 2026, 5:39 PM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate the Safety and Efficacy of CP-690,550 in Patients With Moderate to Severe Crohn's Disease

NCT00615199
View directory record Official record
Conditions
Crohn's Disease
Interventions
CP-690,550, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
39
States / cities
Birmingham, Alabama • Mobile, Alabama • Boulder, Colorado + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2013 · Synced Oct 10, 2026, 5:39 PM EDT
Completed Not applicable Interventional Results available

Digital Behavioral Interventions in Inflammatory Bowel Disease

NCT04861597
View directory record Official record
Conditions
Crohn Disease, Ulcerative Colitis, Inflammatory Bowel Diseases, Stress, Psychological, Depression, Anxiety
Interventions
Internet based cognitive behavioral therapy, Digital mood tracking
Behavioral
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 10, 2026, 5:39 PM EDT
Completed No phase listed Observational

An Observational Study of Lymphoma in Patients With Rheumatoid Arthritis or Crohn's Disease.

NCT00440817
View directory record Official record
Conditions
Lymphoma
Interventions
No intervention
Other
Lead sponsor
Centocor Ortho Biotech Services, L.L.C.
Industry
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
3
States / cities
Highland Park, Illinois • Wichita, Kansas • Albany, New York
Source: ClinicalTrials.gov public record
Updated Apr 10, 2014 · Synced Oct 10, 2026, 5:39 PM EDT
Completed Not applicable Interventional

Yoga for Youth With IBD: a Pilot Feasibility Study

NCT04757935
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Yoga, Adolescents, Crohn Disease, Ulcerative Colitis
Interventions
Yoga
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
10 Years to 21 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Oct 10, 2026, 5:39 PM EDT
Recruiting Not applicable Interventional

Impact of Prebiotics in Ulcerative Colitis

NCT06495658
View directory record Official record
Conditions
Crohn Disease, Ulcerative Colitis
Interventions
Prebiotic
Dietary Supplement
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 85 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 10, 2026, 5:39 PM EDT
Available No phase listed Expanded access

Expanded Access to Vedolizumab for Children and Teenagers With Ulcerative Colitis or Crohn's Disease in the USA

NCT06856135
View directory record Official record
Conditions
Crohn's Disease, Ulcerative Colitis
Interventions
Vedolizumab IV
Drug
Lead sponsor
Takeda
Industry
Eligibility
2 Years and older
U.S. locations
3
States / cities
San Francisco, California • Atlanta, Georgia • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 10, 2026, 5:39 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of Efficacy and Safety of MEDI2070 in Patients With Active, Moderate-to-severe Crohn's Disease.

NCT01714726
View directory record Official record
Conditions
Crohn's Disease
Interventions
MEDI2070, placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
26
States / cities
Encinitas, California • Los Angeles, California • San Diego, California + 22 more
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Oct 10, 2026, 5:39 PM EDT
Terminated Early Phase 1 Interventional

Maintenance Dosing of Vitamin D in Crohn's Disease

NCT03615378
View directory record Official record
Conditions
Crohns Disease, Vitamin D Deficiency
Interventions
5000 IU D3, 1000 IU D3, Placebo
Dietary Supplement
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 10, 2026, 5:39 PM EDT
Completed Not applicable Interventional Results available

Capsule Endoscopy in Inflammatory Bowel Disease (IBD) in Children

NCT02182947
View directory record Official record
Conditions
IBD
Interventions
Capsule endoscopy
Device
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
4 Years to 17 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 11, 2021 · Synced Oct 10, 2026, 5:39 PM EDT
Completed Phase 2 Interventional Results available

A Study of Mirikizumab (LY3074828) in Participants With Active Crohn's Disease

NCT02891226
View directory record Official record
Conditions
Crohn's Disease
Interventions
Mirikizumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
44
States / cities
Huntsville, Alabama • Tucson, Arizona • Garden Grove, California + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2022 · Synced Oct 10, 2026, 5:39 PM EDT
Completed Phase 2 Interventional

A Phase II Study in Patients With Moderate to Severe Active Crohn's Disease

NCT03677648
View directory record Official record
Conditions
Crohn's Disease
Interventions
SHR0302, Placebos
Drug
Lead sponsor
Reistone Biopharma Company Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
6
States / cities
Clearwater, Florida • Lake Wales, Florida • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Oct 10, 2026, 5:39 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease

NCT03782376
View directory record Official record
Conditions
Crohn Disease
Interventions
Ustekinumab approximately 6 mg/kg (IV), Placebo (SC), Placebo (IV), Ustekinumab 90 mg (SC) Group 1, Ustekinumab 90 mg (SC) Group 2
Drug
Lead sponsor
Janssen-Cilag Ltd.
Industry
Eligibility
18 Years and older
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
28
States / cities
La Jolla, California • Colorado Springs, Colorado • Gainesville, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 10, 2026, 5:39 PM EDT
Terminated Phase 2 Interventional Results available

Rifaximin in Patients With Diabetic Gastroparesis

NCT04254549
View directory record Official record
Conditions
Crohn Disease, Diabetic Gastroparesis
Interventions
Rifaximin, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 10, 2026, 5:39 PM EDT
Completed Phase 3 Interventional Results available

A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)

NCT03283085
View directory record Official record
Conditions
Crohn's Disease, Ulcerative Colitis
Interventions
25 mg Ontamalimab, 75 mg Ontamalimab
Drug
Lead sponsor
Shire
Industry
Eligibility
16 Years to 80 Years
Enrollment
557 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
103
States / cities
Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 88 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2024 · Synced Oct 10, 2026, 5:39 PM EDT
Completed Phase 3 Interventional Results available

A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease

NCT02620046
View directory record Official record
Conditions
Colitis, Ulcerative, Crohn's Disease
Interventions
Vedolizumab SC
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
746 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
47
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Wheat Ridge, Colorado + 44 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Oct 10, 2026, 5:39 PM EDT